Patients without diabetes using GLP-1RAs are less likely to develop glaucoma compared with those who use other weight loss therapies.
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback